PUBLISHER: 360iResearch | PRODUCT CODE: 1589053
PUBLISHER: 360iResearch | PRODUCT CODE: 1589053
Conjugate Vaccine Market by Type (Monovalent, Multivalent), Indication (Diphtheria & Pertussis, Influenza, Meningococcal), Pathogen Type, End-User - Global Forecast 2025-2030
The Conjugate Vaccine Market was valued at USD 39.67 billion in 2023, expected to reach USD 43.92 billion in 2024, and is projected to grow at a CAGR of 10.81%, to USD 81.42 billion by 2030.
Conjugate vaccines are critical in preventing invasive diseases like meningitis, pneumonia, and Haemophilus influenzae type b (Hib) by linking polysaccharide antigens to protein carriers, enhancing immunogenicity, especially in young children. Their necessity stems from their ability to generate long-lasting immune responses and herd immunity, reducing disease incidence. Applications mainly include immunization programs targeting infants, young children, and adults with higher susceptibility to certain infectious diseases. End-use scope encompasses hospitals, clinics, public health agencies, and research institutions. Key growth influencers include heightened awareness of vaccine-preventable diseases, government immunization initiatives, and technological advancements in vaccine development. The market is buoyed by persistent investments in healthcare infrastructure and rising demand for pediatric vaccines due to stricter healthcare policies. The COVID-19 pandemic has also underscored the significance of vaccines, broadening the overall market focus on preventive healthcare. Emerging opportunities lie in geographical regions with low immunization coverage, highlighting the potential for expanding market footprints. Strategic collaborations in research and development sectors can propel technological innovations, maximizing market access. However, limitations such as vaccine hesitancy, supply chain disruptions, and high costs of vaccine development could impede growth. Stringent regulatory landscapes requiring extensive clinical evaluations pose additional challenges. Innovation can thrive in the development of thermostable vaccines, novel adjuvant systems, and combination vaccines that address multiple pathogens simultaneously. Exploring new mechanisms of conjugation and alternative carrier proteins can enhance efficacy and broaden protective scope. The nature of the conjugate vaccine market remains highly competitive, with a focus on partnerships between biotech firms, global health bodies, and governmental agencies to expand vaccine accessibility. By leveraging cutting-edge technologies like AI and machine learning in vaccine design, companies can optimize vaccine efficiency and target new pathogenic challenges, positioning themselves as leaders in the field.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 39.67 billion |
| Estimated Year [2024] | USD 43.92 billion |
| Forecast Year [2030] | USD 81.42 billion |
| CAGR (%) | 10.81% |
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Conjugate Vaccine Market
The Conjugate Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Increasing prevalence of infectious diseases and immunosuppression
- Rising adoption of cancer therapeutic vaccines
- Rising number programs to promote vaccination by WHO
- Market Restraints
- Low accessibility to vaccines in remote areas
- Market Opportunities
- Government initiatives spreading awareness about infectious diseases
- Advancement in technology for producing novel conjugate vaccines
- Market Challenges
- Complexity of production procedure of conjugate vaccine
Porter's Five Forces: A Strategic Tool for Navigating the Conjugate Vaccine Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Conjugate Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Conjugate Vaccine Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Conjugate Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Conjugate Vaccine Market
A detailed market share analysis in the Conjugate Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Conjugate Vaccine Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Conjugate Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Conjugate Vaccine Market
A strategic analysis of the Conjugate Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Conjugate Vaccine Market, highlighting leading vendors and their innovative profiles. These include Bavarian Nordic, Bharat Biotech Ltd., Bio-Med Limited, Biological E. Limited, Biological E. Ltd, CSL Limited, GlaxoSmithKline, plc., Merck and Company, Novartis AG, Nuron Biotech Inc., Pfizer, Inc., Sanofi Pasteur U.S., LLC, Serum Institute of India Pvt. Ltd., Taj Pharmaceuticals Limited, and Vaxcyte, Inc..
Market Segmentation & Coverage
This research report categorizes the Conjugate Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Type, market is studied across Monovalent and Multivalent.
- Based on Indication, market is studied across Diphtheria & Pertussis, Influenza, Meningococcal, and Pneumococcal.
- Based on Pathogen Type, market is studied across Bacterial Conjugate Vaccine, Combination Conjugate Vaccine, and Viral Conjugate Vaccine.
- Based on End-User, market is studied across Adults and Children.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing prevalence of infectious diseases and immunosuppression
- 5.1.1.2. Rising adoption of cancer therapeutic vaccines
- 5.1.1.3. Rising number programs to promote vaccination by WHO
- 5.1.2. Restraints
- 5.1.2.1. Low accessibility to vaccines in remote areas
- 5.1.3. Opportunities
- 5.1.3.1. Government initiatives spreading awareness about infectious diseases
- 5.1.3.2. Advancement in technology for producing novel conjugate vaccines
- 5.1.4. Challenges
- 5.1.4.1. Complexity of production procedure of conjugate vaccine
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Conjugate Vaccine Market, by Type
- 6.1. Introduction
- 6.2. Monovalent
- 6.3. Multivalent
7. Conjugate Vaccine Market, by Indication
- 7.1. Introduction
- 7.2. Diphtheria & Pertussis
- 7.3. Influenza
- 7.4. Meningococcal
- 7.5. Pneumococcal
8. Conjugate Vaccine Market, by Pathogen Type
- 8.1. Introduction
- 8.2. Bacterial Conjugate Vaccine
- 8.3. Combination Conjugate Vaccine
- 8.4. Viral Conjugate Vaccine
9. Conjugate Vaccine Market, by End-User
- 9.1. Introduction
- 9.2. Adults
- 9.3. Children
10. Americas Conjugate Vaccine Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
11. Asia-Pacific Conjugate Vaccine Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
12. Europe, Middle East & Africa Conjugate Vaccine Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. Bavarian Nordic
- 2. Bharat Biotech Ltd.
- 3. Bio-Med Limited
- 4. Biological E. Limited
- 5. Biological E. Ltd
- 6. CSL Limited
- 7. GlaxoSmithKline, plc.
- 8. Merck and Company
- 9. Novartis AG
- 10. Nuron Biotech Inc.
- 11. Pfizer, Inc.
- 12. Sanofi Pasteur U.S., LLC
- 13. Serum Institute of India Pvt. Ltd.
- 14. Taj Pharmaceuticals Limited
- 15. Vaxcyte, Inc.
LIST OF FIGURES
- FIGURE 1. CONJUGATE VACCINE MARKET RESEARCH PROCESS
- FIGURE 2. CONJUGATE VACCINE MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2023 VS 2030 (%)
- FIGURE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 15. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 17. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 19. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 22. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 23. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. CONJUGATE VACCINE MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. CONJUGATE VACCINE MARKET DYNAMICS
- TABLE 7. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MONOVALENT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MULTIVALENT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY DIPHTHERIA & PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 16. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY BACTERIAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COMBINATION CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 18. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY VIRAL CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 19. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 20. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 21. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
- TABLE 22. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 23. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 24. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 25. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 26. AMERICAS CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 27. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 28. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 29. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 30. ARGENTINA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 31. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 32. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 33. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 34. BRAZIL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 35. CANADA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 36. CANADA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 37. CANADA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 38. CANADA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 39. MEXICO CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 40. MEXICO CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 41. MEXICO CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 42. MEXICO CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 43. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 44. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 45. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 46. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 47. UNITED STATES CONJUGATE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 48. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 49. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 50. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 51. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 52. ASIA-PACIFIC CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 53. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 54. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 55. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 56. AUSTRALIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 57. CHINA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 58. CHINA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 59. CHINA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 60. CHINA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 61. INDIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 62. INDIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 63. INDIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 64. INDIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 65. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 66. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 67. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 68. INDONESIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 69. JAPAN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 70. JAPAN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 71. JAPAN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 72. JAPAN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 73. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 74. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 75. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 76. MALAYSIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 77. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 78. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 79. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 80. PHILIPPINES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 81. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 82. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 83. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 84. SINGAPORE CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 85. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 86. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 87. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 88. SOUTH KOREA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 89. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 90. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 91. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 92. TAIWAN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 93. THAILAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 94. THAILAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 95. THAILAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 96. THAILAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 97. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 98. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 99. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 100. VIETNAM CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 101. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 102. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 103. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 104. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 105. EUROPE, MIDDLE EAST & AFRICA CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 106. DENMARK CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 107. DENMARK CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 108. DENMARK CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 109. DENMARK CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 110. EGYPT CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 111. EGYPT CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 112. EGYPT CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 113. EGYPT CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 114. FINLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 115. FINLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 116. FINLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 117. FINLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 118. FRANCE CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 119. FRANCE CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 120. FRANCE CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 121. FRANCE CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 122. GERMANY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 123. GERMANY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 124. GERMANY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 125. GERMANY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 126. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 127. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 128. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 129. ISRAEL CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 130. ITALY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 131. ITALY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 132. ITALY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 133. ITALY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 134. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 135. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 136. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 137. NETHERLANDS CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 138. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 139. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 140. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 141. NIGERIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 142. NORWAY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 143. NORWAY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 144. NORWAY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 145. NORWAY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 146. POLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 147. POLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 148. POLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 149. POLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 150. QATAR CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 151. QATAR CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 152. QATAR CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 153. QATAR CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 154. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 155. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 156. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 157. RUSSIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 158. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 159. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 160. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 161. SAUDI ARABIA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 162. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 163. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 164. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 165. SOUTH AFRICA CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 166. SPAIN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 167. SPAIN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 168. SPAIN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 169. SPAIN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 170. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 171. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 172. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 173. SWEDEN CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 174. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 175. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 176. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 177. SWITZERLAND CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 178. TURKEY CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 179. TURKEY CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 180. TURKEY CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 181. TURKEY CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 182. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 183. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 184. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 185. UNITED ARAB EMIRATES CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 186. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
- TABLE 187. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
- TABLE 188. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
- TABLE 189. UNITED KINGDOM CONJUGATE VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 190. CONJUGATE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 191. CONJUGATE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
